AI-POWERED
DNA ENGINEERING
The Software Engine for Scalable Protein Production
MNDL BIO ENABLES SCALABLE PROTEIN PRODUCTION BY OPTIMIZING DNA
Technology Features
Physics-Guided AI
Fusing biophysical modeling with advanced machine learning to navigate DNA sequence space and optimize expression beyond simple codon usage.
Whole-Construct Design
Engineering the entire genetic system, tuning mRNA folding and ribosomal traffic, to drive consistent, high-yield production in any host.
Proven Scalability
Validated across dozens of organisms and high-value verticals, including antibodies, industrial enzymes, and AgTech, with documented yield improvements.
Selected Case Studies
Solving Expression Bottlenecks with Smart Genetic Design
Human G6PD in e. coli
Engineered Enzyme for Industrial Biotech
15 kDa Protein in a Bacterial System
As part of an internal benchmarking initiative, MNDL Bio undertook the challenge of engineering high-yield expression of human glucose-6-phosphate dehydrogenase (hG6PD) in Escherichia coli BL21(DE3) — a notoriously difficult task due to the enzyme’s complex folding requirements and susceptibility to truncation and misfolding in prokaryotic systems. G6PD is a cytoplasmic enzyme central to the pentose phosphate pathway, catalyzing the production of NADPH — a cofactor essential for maintaining redox balance and driving biosynthetic reactions. Its commercial relevance spans enzyme replacement therapies, NADPH-coupled diagnostics, and biomanufacturing, yet scalable recombinant production remains a longstanding challenge. To address this, MNDL applied its proprietary sequence optimization platform, iteratively testing multiple algorithmic strategies — including advanced codon usage modeling, untranslated region (UTR) engineering, and non-coding sequence adaptations. Several optimized variants were evaluated, leading to improved expression of the full-length enzyme across most designs. This effort not only demonstrates the robustness and flexibility of MNDL's AI-powered design pipeline but also reinforces its applicability to complex, clinically relevant targets with high commercial impact.
For a commercial client in the industrial biotechnology sector, MNDL Bio was tasked with improving the expression of a custom-engineered enzyme in Escherichia coli, which had previously failed to meet target yield thresholds. Leveraging its advanced sequence optimization platform, MNDL designed and screened 10 construct variants using a combination of predictive modeling, codon and non-coding region optimization, and host-specific design principles. One of the variants achieved a ~2.5-fold increase in expression relative to the original construct. This successful optimization highlights MNDL’s ability to overcome a major bottleneck in biomanufacturing: the low expression of engineered or non-native enzymes in microbial systems. Enzymes are at the heart of critical industrial applications — spanning biopharmaceuticals, diagnostics, food and feed processing, textiles, and sustainable biofuels — with the global enzyme market projected to surpass $20 billion by 2028. In these contexts, even modest gains in enzyme titer can dramatically enhance process efficiency, cost-effectiveness, and scalability. MNDL’s platform enables clients to meet these demands by delivering expression-optimized constructs tailored to specific production constraints, ultimately accelerating innovation across the synthetic biology value chain.
In a project for a commercial client operating in a highly cost-sensitive sector, MNDL Bio was tasked with enabling scalable expression of a ~15 kDa recombinant protein using an E. coli-based cell-free expression system. The native (wild-type) sequence yielded negligible protein levels, making it unsuitable for production-scale workflows. To address this, MNDL deployed a suite of its proprietary optimization algorithms — combining machine learning, deep learning, and biophysical models — to generate and test multiple synthetic variants of the gene. The results were striking: several of MNDL’s designed sequences achieved a ~9.5- to 15-fold increase in protein expression compared to the original sequence. This dramatic improvement underscores the platform’s ability to overcome fundamental expression challenges in cell-free systems — an increasingly attractive alternative to live-cell expression for rapid prototyping, diagnostics, and precision biomanufacturing. In industries where protein cost directly affects product viability, such expression gains can meaningfully shift the economics of production. MNDL’s ability to deliver such performance without compromising sequence fidelity or function demonstrates its critical value in accelerating the development of high-efficiency bioproducts in next-generation manufacturing systems.
Leadership
Dedication. Expertise. Passion.
Our team unites leading expertise in AI and biophysical modeling with proven business and R&D leadership. Together, we are productizing breakthrough AI to redefine the limits of gene expression and protein production.
Research Powering Our Solutions
Read about our peer-reviewed publications, science and magic.
Our Sectors
MNDL can assist with medical, agriculture, pharmaceutical, clothing, etc.
Medical
MNDL can assist with medical, agriculture, pharmaceutical, clothing, etc.
Pharmaceutical
MNDL can assist with medical, agriculture, pharmaceutical, clothing, etc.
Agriculture
MNDL can assist with medical, agriculture, pharmaceutical, clothing, etc.
Clothing
MNDL can assist with medical, agriculture, pharmaceutical, clothing, etc.
From the News...
From our partners and friends...
TESTIMONIAL
MNDL Bio helped us improve the expression of our industrial enzyme for food applications in a microbial expression system. We achieved a clear increase in expression levels, reached efficiently and with strong technical support throughout the process. A productive and reliable collaboration.
Ziv Zwighaft
CEO, Ambrosia Bio
Our Investors & Partners
